• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

molnupiravir

coronavirus Omicron
Posted inCOVID-19, Infections, Research

Omicron Treatment: Most Effective Drugs

by Tanya von Reuss and Timur Burkhanayev August 31, 2022September 8, 2022

Efficacy of antivirals and monoclonal antibodies for outpatient treatment of COVID-19 infection with the Omicron variant of SARS-CoV-2 coronavirus.

Paxlovid (nirmatrelvir + ritonavir)
Posted inCOVID-19, Infections, Regulatory

Paxlovid for COVID-19 Treatment. All Details

by Tanya von Reuss and Timur Burkhanayev August 24, 2022March 10, 2024

Paxlovid: treatment efficacy, “Paxlovid mouth”, COVID-19 rebound, management of Omicron variant, treatment resistance, generics, mechanism of action, price.

Molnupiravir
Posted inCOVID-19, Infections, New Drugs, Regulatory

Molnupiravir Approved in the U.S.

by Tanya von Reuss December 23, 2021September 8, 2022

An oral antiviral drug by Merck & Co. has joined the armamentarium of the pharmacological fight against COVID-19.

Posted inClinical Trials, COVID-19, Infections

Molnupiravir: New Effective Pill for Coronavirus. All That We Know

by Tanya von Reuss and Nik Resovski December 14, 2021September 8, 2022

Molnupiravir pills by Merck & Co. can help COVID-19 patients avoid going to the hospital or dying.

Posted inCOVID-19, Infections, Regulatory

Molnupiravir: What U.S. Experts Said

by Julia Mardi December 1, 2021September 8, 2022

FDA scientists took a detailed look at molnupiravir for treating COVID-19.

molnupiravir
Posted inCOVID-19, Infections, New Drugs, Regulatory

Lagevrio: New Antiviral Drug to Treat COVID-19

by Julia Mardi November 4, 2021September 8, 2022

The oral antiviral drug molnupiravir by Merck & Co.

BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×